Processa Pharmaceuticals, Inc.
PCSA· Nasdaq
PCSAProcessa Pharmaceuticals, Inc.
Filed Mar 25, 2021 · 10-K · 84 days after period end · 0001493152-21-006807
derived · Computed from the longer spans the company filed.
| Metric | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures | Q4 2017 |
|---|---|---|---|---|
| Net Income | -$9.73M | -$774.44K | -$609.35K | -$633.86K |
| EPS Diluted | — | — | — | -$0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Dec 31, 2020 · filed Mar 25, 2021 · 84 d after period end
